Citadel Advisors
MGX icon

Citadel Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Citadel Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2K Buy
17,851
+858
+5% +$1.15K ﹤0.01% 13394
2026
Q1 		$22.8K Sell
16,993
-161,179
-90% -$250K ﹤0.01% 12640
2025
Q4 		$289K Buy
+178,172
New +$386K ﹤0.01% 10231
2025
Q3 		– Sell
-60,624
Closed -$89.7K – 14343
2025
Q2 		$89.7K Buy
+60,624
New +$94.9K ﹤0.01% 11417
2025
Q1 		– Sell
-149,698
Closed -$540K – 15739
2024
Q4 		$540K Sell
149,698
-654,764
-81% -$1.58M ﹤0.01% 8380
2024
Q3 		$1.75M Buy
804,462
+74,610
+10% +$259K ﹤0.01% 5795
2024
Q2 		$2.93M Buy
729,852
+5,951
+0.8% +$40.9K ﹤0.01% 4598
2024
Q1 		$7.52M Buy
+723,901
New +$8.32M ﹤0.01% 3338

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's MGX Position: Q2 2026 in Review

Citadel Advisors increased its Metagenomi Therapeutics (MGX) stake by 5% in Q2 2026, buying an estimated $1.15K and bringing the position to 17,851 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #13394.

Citadel Advisors first reported a position in MGX in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.52M in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Citadel Advisors held 17,851 shares of Metagenomi Therapeutics worth $21.2K as of Q2 2026.
  • Citadel Advisors bought 858 Metagenomi Therapeutics shares in Q2 2026, an estimated $1.15K.
  • Metagenomi Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13394 holding.
  • Citadel Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Citadel Advisors's Metagenomi Therapeutics position peaked at $7.52M in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.